MedTrace Logo

REsponsiveness to CLOpidogrel and Stent-related Events in Acute Coronary Syndromes (RECLOSE 2 - ACS)

NCT01231035 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1789

Last updated 2011-07-25

No results posted yet for this study

Summary

The main objective of the project is to assess the long-term prognostic impact of residual platelet reactivity after optimal antiplatelet therapy in a large cohort of patients with acute coronary syndrome undergoing invasive strategy.

Follow-up length will be at least 24 months. The primary end-point of the study will be a composite of death, myocardial infarction, urgent target vessel revascularization, stent thrombosis or stroke.

Conditions

  • Acute Cardiac Syndrome
  • Stent Thrombosis
  • Platelet Function
  • Antiplatelet Therapy

Sponsors & Collaborators

  • Careggi Hospital

    lead OTHER

Principal Investigators

  • David Antoniucci, MD · Careggi Hospital, Division of Invasive Cardiology

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2011-03-31
Completion
2011-03-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01231035 on ClinicalTrials.gov